Vétoquinol USA Receives Exclusive U. S. Distribution Rights to Zylkène® from Orsco Laboratoire Vétérinaire
Zylkène® is a proven tool to help veterinarians manage stress in companion animals
Fort Worth, Texas (PRWEB) August 1, 2010
Vétoquinol USA (www. vetoquinolusa. com) introduced Zylkène® today to the U. S. market at the American College of Veterinary Behaviorists (ACVB)/American Veterinary Society of Animal Behavior (AVSAB) Behavior Symposium in Atlanta, GA. Vétoquinol USA has the exclusive U. S. distribution rights for Zylkène® through a contract signed by Orsco Laboratoire Vétérinaire and Vétoquinol.
Companion animals often are exposed to stressful situations such as adoption, weaning, hospitalization, changing owners or homes or reproducing. Failure to adjust to new situations in a reasonable period can result in behavioral problems, such as feeding or digestive problems, inappropriate urination or defecation, destructive behavior, running away, or aggression.
Zylkène® contains a patented decapeptide and helps companion animals overcome periods of stress. Zylkène® is very well tolerated, non-habit forming and has no rebound effect. Its effectiveness has been demonstrated in a number of clinical studies in dogs and cats. Its formula is protected by a U. S. patent.
Zylkène® has been marketed in Europe since 2006. During that time, it has become one of the leading products used to help manage stress in companion animals.
“Zylkène® gives veterinarians a new, innovative solution to help pet owners manage behavior issues. We estimate that nearly 10% of all dogs and cats suffer from behavioral disorders. We are excited about bringing Zylkène® to veterinary behaviorists and veterinarians in the U. S.,” stated Manny Martinez, Country Manager.
Vétoquinol USA, based in Fort Worth, Texas, is owned by Vétoquinol an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 9th largest animal health care laboratory in the world. More than 80 percent of its revenues are generated outside France.
Vétoquinol’s business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain and anti-inflammatory, and cardiology/nephrology.
The Group currently distributes its products in more than 100 countries throughout Europe, North American and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has more than 1,550 employees worldwide. For more information: www. vetoquinolusa. com
# # #